CMS is considering the following measures for the Hospital Value Based Purchasing Program:
Measure:
|
Reference
|
First listed here:
|
|
Spending per Hospital Patient with Medicare (also known as Medicare Spending per Beneficiary)- Opens in a new window
|
MSPB
|
4/21/2011 |
|
Serious Complications and Deaths- Opens in a new window
|
AHRQ
|
3/3/2011
|
|
Hospital Acquired Conditions- Opens in a new window
|
HAC
|
3/3/2011
|
|
Emergency Department Wait Times- Opens in a new window
View Data- Opens in a new window
|
ED-1 and ED-2
|
4/21/2011
|
|
Heart Patients Given a Prescription for Drugs called Statins at Discharge. (AMI-10: Statin Prescribed at Discharge
|
AMI-10
|
4/21/2011
|
|
Central Line-associated Blood Stream Infection
|
CLABSI
|
4/21/2011
|
|
Surgical Site Infections
|
SSI SRI
|
4/21/2011
|
|
Immunization for Influenza
|
IMM-1
|
4/21/2011
|
|
Immunization for Pneumonia
|
IMM-2
|
4/21/2011
|
|
Percent of patients with an ischemic stroke or a hemorrhagic stroke and who are non-ambulatory should start receiving deep vein thrombosis (DVT) prophylaxis by end of hospital day two.
|
STK-1
|
10/13/2011
|
|
Percent of patients with an ischemic stroke prescribed antithrombotic therapy at discharge.
|
STK-2
|
10/13/2011
|
|
Percent of patients with an ischemic stroke with atrial fibrillation discharged on anticoagulation therapy.
|
STK-3
|
10/13/2011
|
|
Percent of acute ischemic stroke patients who arrive at the hospital within 120 minutes (2 hours) of time last known well and for whom IV t-PA was initiated at this hospital within 180 minutes (3 hours) of time last known well.
|
STK-4
|
10/13/2011
|
|
Percent of patients with ischemic stroke who receive antithrombotic therapy by the end of hospital day two.
|
STK-5
|
10/13/2011
|
|
Percent of ischemic stroke patients with LDL >/= 100 mg/dL, or LDL not measured, or, who were on cholesterol reducing therapy prior to hospitalization are discharged on a statin medication.
|
STK-6
|
10/13/2011
|
|
Percent of patients with ischemic or hemorrhagic stroke or their caregivers who were given education or educational materials during the hospital stay addressing all of the following: personal risk factors for stroke, warning signs for stroke, activation of emergency.
|
STK-8
|
10/13/2011
|
|
Percent of patients with an ischemic stroke or hemorrhagic stroke who were assessed for rehabilitation services.
|
STK-10
|
10/13/2011
|
|
Percent of patients who received venous thromboembolism (VTE) prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission.
|
VTE-1
|
10/13/2011
|
|
Percent of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or surgery end date for surgeries that start the day of or the day after ICU admission (or transfer).
|
VTE-2
|
10/13/2011
|
|
Percent of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than 5 days of overlap therapy, they must be discharged on both medications. Overlap therapy must be administered for at least 5 days with an international normalized ratio (INR) = 2 prior to discontinuation of the parenteral anticoagulation therapy or the patient must be discharged on both medications.
|
VTE-3
|
10/13/2011
|
|
Percent of patients diagnosed with confirmed VTE who received intravenous (IV) UFH therapy dosages AND had their platelet counts monitored using defined parameters such as a nomogram.
|
VTE-4
|
10/13/2011
|
|
Percent of patients diagnosed with confirmed VTE that are discharged to home, to home with home health or home hospice on warfarin with written discharge instructions that address all four criteria: Compliance issues, dietary advice, follow-up monitoring, and information about the potential for adverse drug reactions/interactions.
|
VTE-5
|
10/13/2011
|
|
Percent of patients diagnosed with confirmed VTE during hospitalization (not present on arrival) who did not receive VTE prophylaxis between hospital admission and the day before the VTE diagnostic testing order date.
|
VTE-6
|
10/13/2011
|
|
Methicillin-resistant Staphylococcus aureus (MRSA) infection with onset in the community in an individual lacking established MRSA risk factors, such as recent hospitalization, surgery, residence in a long-term care facility, receipt of dialysis, or presence of invasive medical devices.
|
MRSA Bacterimia SRI
|
10/13/2011
|
|
Clostridium difficile is responsible for a spectrum of C. difficile infections (CDI) [originally referred to as C. difficile-associated disease or CDAD], including uncomplicated diarrhea, pseudomembranous colitis, and toxic megacolon which can, in some instances, lead to sepsis and even death.
|
C. diff SRI
|
10/13/2011
|
|
The measure enables a healthcare facility to record information on influenza vaccination status.
|
HCP
|
10/13/2011
|
|
Number of catheter associated urinary tract infection (UTIs).
|
CAUTI
|
10/13/2011
|